This program is not sponsored or programmed by the AAAAI.

Sponsored by Sanofi and Regeneron Pharmaceuticals.

This program will improve the scientific and medical knowledge of emerging targets and therapies for moderate-to-severe atopic dermatitis (AD) and asthma; review guideline adherence strategies for managing patients with AD or asthma; illuminate new and evolving, immune-based therapeutic strategies that have the potential for improving clinical remissions; address the clinical burden of AD with a focus on duration of treatment, quality-of-life issues, disease, co-morbidities, and the evolution of AD from the pediatric years to adulthood; and review best practice benchmarks among specialists caring for patients at high risk for resistant disease, severe disease, and/or treatment failures.